Respiri Limited (ASX:RSH), an eHealth SaaS Company supporting respiratory health management, has finalised patient selection and begun onboarding for its Minnesota Lung Center wheezo RPM pilot programme.
RPM partner Access Telehealth will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring to these patients, under the supervision of MLC.
The pilot programme has been reduced from three-months to two-months after which the wheezo RPM programme will be integrated into MLC systems and workflow and rolled-out as part of standard of care to respiratory patients with both asthma and/or COPD (Chronic Obstructive Pulmonary Disease).
RPM (CPT) reimbursement codes from this program will be processed through Centres for Medicare and Medicaid Services (CMS) and private insurers to ensure MLC is remunerated for providing this important and cost-effective patient service.
In addition to the device sale, Respiri will receive recurring RPM revenues per patient, per month for reimbursed services claimed by MLC which will include relevant RPM and possible Chronic Care Management (CCM) CPT codes.
MLC provides ongoing care to thousands of existing respiratory patients and to new patient referrals from other physicians, all of which are potential candidates for the wheezo RPM programme.
The programme has the potential to make material differences to the lives of many respiratory patients,” CEO, Marjan Mikel, said.
“The relationship we have developed with Minnesota Lung Centre and Access Telehealth allows Respiri to deliver a unique world class solution and future commercial rewards.”
wheezo RPM programme
Respiri together with RPM partners are in advanced discussions with a number of other potential wheezo RPM customers who have recognised the benefits of introducing RPM services as part of their patient standard of care.
